Peter Ragnhammar

2.7k total citations
66 papers, 2.2k citations indexed

About

Peter Ragnhammar is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Peter Ragnhammar has authored 66 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 28 papers in Immunology and 21 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Peter Ragnhammar's work include Colorectal Cancer Treatments and Studies (28 papers), Immunotherapy and Immune Responses (25 papers) and Monoclonal and Polyclonal Antibodies Research (17 papers). Peter Ragnhammar is often cited by papers focused on Colorectal Cancer Treatments and Studies (28 papers), Immunotherapy and Immune Responses (25 papers) and Monoclonal and Polyclonal Antibodies Research (17 papers). Peter Ragnhammar collaborates with scholars based in Sweden, United Kingdom and Belarus. Peter Ragnhammar's co-authors include David Edler, Marja Hallström, Bengt Glimelius, Jan‐Erik Frödin, I Magnusson, Håkan Mellstedt, Henric Blomgren, Jan Fagerberg, Peter Nygren and Patrick G. Johnston and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Scientific Reports.

In The Last Decade

Peter Ragnhammar

66 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Ragnhammar Sweden	26	1.3k	675	514	461	397	66	2.2k
Randeep Sangha Canada	23	1.3k 1.0×	330 0.5×	590 1.1×	210 0.5×	490 1.2×	72	2.3k
James Posey United States	26	1.8k 1.3×	179 0.3×	723 1.4×	228 0.5×	225 0.6×	66	2.7k
Alejandro Martı́n Spain	25	1.4k 1.1×	465 0.7×	845 1.6×	183 0.4×	861 2.2×	128	2.8k
Matthew Boente United States	24	1.5k 1.1×	351 0.5×	902 1.8×	132 0.3×	485 1.2×	54	3.7k
Mark Harries United Kingdom	25	1.1k 0.8×	354 0.5×	579 1.1×	337 0.7×	182 0.5×	62	1.9k
Gianluca Spitaleri Italy	26	1.1k 0.9×	313 0.5×	504 1.0×	403 0.9×	267 0.7×	83	2.1k
Yoichi Naito Japan	27	1.7k 1.3×	355 0.5×	623 1.2×	348 0.8×	220 0.6×	150	2.7k
A. Keith Stewart Canada	37	1.4k 1.1×	549 0.8×	2.4k 4.6×	221 0.5×	483 1.2×	100	3.9k
J Garcı́a-Conde Spain	35	2.0k 1.6×	596 0.9×	954 1.9×	361 0.8×	1.1k 2.8×	104	3.9k
Morten Mau‐Sørensen Denmark	28	1.2k 0.9×	276 0.4×	1.1k 2.1×	187 0.4×	310 0.8×	130	2.7k

Countries citing papers authored by Peter Ragnhammar

Since Specialization

Citations

This map shows the geographic impact of Peter Ragnhammar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Ragnhammar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Ragnhammar more than expected).

Fields of papers citing papers by Peter Ragnhammar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Ragnhammar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Ragnhammar. The network helps show where Peter Ragnhammar may publish in the future.

Co-authorship network of co-authors of Peter Ragnhammar

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Ragnhammar. A scholar is included among the top collaborators of Peter Ragnhammar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Ragnhammar. Peter Ragnhammar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Villabona, Lisa, Giuseppe Masucci, & Peter Ragnhammar. (2019). Gender differences in prognostic value of immune-related biomarkers in colon cancer patients randomized to surgery or surgery and adjuvant chemotherapy treatment.. Journal of Clinical Oncology. 37(15_suppl). 3603–3603. 1 indexed citations

Mezheyeuski, Artur, Mercedes Herrera, Erik Osterman, et al.. (2019). Stroma-normalised vessel density predicts benefit from adjuvant fluorouracil-based chemotherapy in patients with stage II/III colon cancer. British Journal of Cancer. 121(4). 303–311. 3 indexed citations

Hallström, Marja, et al.. (2016). HER3 expression is correlated to distally located and low-grade colon cancer. Acta Oncologica. 55(7). 875–880. 9 indexed citations

Hallström, Marja, et al.. (2013). HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome. European Journal of Cancer. 50(3). 656–662. 44 indexed citations

Öhrling, Katarina, David Edler, Marja Hallström, & Peter Ragnhammar. (2010). Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer. Acta Oncologica. 49(6). 797–804. 25 indexed citations

Edler, David, Katarina Öhrling, Marja Hallström, et al.. (2008). The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer – A pilot study. European Journal of Cancer. 45(4). 705–712. 41 indexed citations

Liljefors, Maria, et al.. (2003). Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17‐1A. International Journal of Cancer. 105(5). 717–723. 50 indexed citations

Frödin, Jan‐Erik, et al.. (2002). MAb17-1A and Cytokines for the Treatment of Patients with Colorectal Carcinoma. PubMed. 21(2). 99–101. 7 indexed citations

Glimelius, Ingrid, Jonas Bergh, L. Brandt, et al.. (2001). The Swedish Council on Technology Assessment in Health Care (SBU) Systematic Overview of Chemotherapy Effects in Some Major Tumour Types - Summary and Conclusions. Acta Oncologica. 40(2). 135–154. 31 indexed citations

10.

Ragnhammar, Peter, Larsolof Hafström, Peter Nygren, & Bengt Glimelius. (2001). A Systematic Overview of Chemotherapy Effects in Colorectal Cancer. Acta Oncologica. 40(2). 282–308. 185 indexed citations

11.

Mellstedt, Håkan, Jan Fagerberg, Jan‐Erik Frödin, et al.. (2000). Ga733/EpCAM as a Target for Passive and Active Specific Immunotherapy in Patients with Colorectal Carcinoma. Annals of the New York Academy of Sciences. 910(1). 254–262. 25 indexed citations

12.

Ragnhammar, Peter, Jan Fagerberg, Jan‐Erik Frödin, et al.. (1999). Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma. Cancer Immunology Immunotherapy. 48(8). 463–470. 16 indexed citations

13.

Edler, David, Henric Blomgren, C J Allegra, et al.. (1997). Immunohistochemical determination of thymidylate synthase in colorectal cancer—methodological studies. European Journal of Cancer. 33(13). 2278–2281. 45 indexed citations

14.

Ragnhammar, Peter. (1996). Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors. Medical Oncology. 13(3). 167–176. 21 indexed citations

15.

Ragnhammar, Peter & Meenu Wadhwa. (1996). Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy. Medical Oncology. 13(3). 161–166. 15 indexed citations

16.

Ragnhammar, Peter & Henric Blomgren. (1995). How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer. Medical Oncology. 12(3). 187–201. 5 indexed citations

17.

Ragnhammar, Peter, Jan Fagerberg, I Magnusson, et al.. (1995). Subcutaneous Interleukin-2 and Alpha-Interferon in Advanced Colorectal Carcinoma. - A Phase II Study. PubMed. 10(1). 5–12. 3 indexed citations

18.

Ragnhammar, Peter, et al.. (1992). Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor. Cancer Immunology Immunotherapy. 35(3). 158–164. 18 indexed citations

19.

Masucci, Giuseppe, Peter Ragnhammar, Peter Wersäll, & Håkan Mellstedt. (1990). Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A). Cancer Immunology Immunotherapy. 31(4). 231–235. 45 indexed citations

20.

Mellstedt, Håkan, Jan‐Erik Frödin, Peter Ragnhammar, et al.. (1989). The clinical use of monoclonal antibodies, MAb 17-1A, in the treatment of patients with metastatic colorectal carcinoma. Medical Oncology and Tumor Pharmacotherapy. 6(1). 99–107. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact